Viking Therapeutics Drops — Analysts Call It a Buying Opportunity

Viking Therapeutics shares have undergone a notable correction, drawing the attention of investors tracking the biotechnology sector. The company is at the forefront of obesity drug development, one of the hottest areas in modern pharma. Wall Street analysts are nearly unanimous in recommending investors buy the dip, citing a robust clinical pipeline. The potential market for obesity treatments is estimated in the hundreds of billions of dollars, with competitor successes validating patient and insurer demand. Risks remain, as clinical trials could disappoint and competition in the sector is fierce. Nevertheless, the risk-reward profile, according to most experts, favors buying at current price levels.